10-Q
Quarterly Report
ALTO INGREDIENTS, INC.
ALTO
NASDAQ
CIK: 778164
File #: 000-21467
Balance Sheet
50 line items · 2 periods
XBRL
| Item | Sep 30, 2024 | Dec 31, 2023 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 33,591,000 | 30,014,000 |
Restricted cash | 4,903,000 | 15,466,000 |
Cash collateral balance | 4,903,000 | 15,466,000 |
Accounts receivable, net (net of allowance for credit losses of $50 and $85, respectively) | 52,038,000 | 58,729,000 |
Inventories | 48,014,000 | 52,611,000 |
Derivative instruments | 36,000 | 2,412,000 |
Commodity contracts | 36,000 | 2,412,000 |
Derivative Financial Instruments, Assets | 36,000 | 2,412,000 |
Derivative Financial Instruments, Assets - Level 1 | 36,000 | 2,412,000 |
Other current assets | 6,568,000 | 9,538,000 |
Total current assets | 145,150,000 | 168,770,000 |
Property and equipment, net | 238,892,000 | 248,748,000 |
Other Assets: | ||
Right of use operating lease assets, net | 19,283,000 | 22,597,000 |
Intangible assets, net | 8,057,000 | 8,498,000 |
Other assets | 6,029,000 | 5,628,000 |
Total other assets | 33,369,000 | 36,723,000 |
Total Assets | 417,411,000 | 454,241,000 |
Pekin Campus | 227,491,000 | 251,048,000 |
Marketing and distribution | 90,215,000 | 101,196,000 |
Western production | 63,920,000 | 57,533,000 |
Corporate and Other | 35,785,000 | 44,464,000 |
Current Liabilities: | ||
Accounts payable | 17,205,000 | 20,752,000 |
Accrued liabilities | 14,255,000 | 20,205,000 |
Current portion – operating leases | 4,440,000 | 4,333,000 |
Derivative instruments | 3,394,000 | 13,849,000 |
Commodity contracts | 3,394,000 | 13,849,000 |
Derivative Financial Instruments, Liabilities | (3,394,000) | 13,849,000 |
Level 1 - Derivative Financial Instruments, Liabilities | (3,394,000) | 13,849,000 |
Other current liabilities | 5,808,000 | 6,149,000 |
Total current liabilities | 45,102,000 | 65,288,000 |
Long-term debt, net | 83,342,000 | 82,097,000 |
Operating leases, net of current portion | 15,740,000 | 19,029,000 |
Other liabilities | 9,302,000 | 8,270,000 |
Total Liabilities | 153,486,000 | 174,684,000 |
Stockholders’ Equity: | ||
Preferred stock, $0.001 par value; 10,000 shares authorized; Series A: 1,684 shares authorized; no shares issued and outstanding as of September 30, 2024 and December 31, 2023; Series B: 1,581 shares authorized; 927 shares issued and outstanding as of September 30, 2024 and December 31, 2023; liquidation preference of $18,075 as of September 30, 2024 | 1,000 | 1,000 |
Common stock, value | 77,000 | 76,000 |
Additional paid-in capital | 1,043,501,000 | 1,040,912,000 |
Accumulated other comprehensive income | 2,481,000 | 2,481,000 |
Accumulated deficit | (782,135,000) | (763,913,000) |
Total stockholders’ equity | 263,925,000 | 279,557,000 |
Preferred Stock | 1,000 | 1,000 |
Common Stock | 77,000 | 76,000 |
Additional Paid-In Capital | 1,043,501,000 | 1,040,912,000 |
Accumulated Deficit | (782,135,000) | (763,913,000) |
Accum. Other Comprehensive Income | 2,481,000 | 2,481,000 |
Total Liabilities and Stockholders’ Equity | 417,411,000 | 454,241,000 |